The world’s Largest Sharp Brain Virtual Experts Marketplace Just a click Away
Levels Tought:
University
| Teaching Since: | Apr 2017 |
| Last Sign in: | 438 Weeks Ago, 1 Day Ago |
| Questions Answered: | 9562 |
| Tutorials Posted: | 9559 |
bachelor in business administration
Polytechnic State University Sanluis
Jan-2006 - Nov-2010
CPA
Polytechnic State University
Jan-2012 - Nov-2016
Professor
Harvard Square Academy (HS2)
Mar-2012 - Present
 Subjects with preexisting cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9804 overweight or obese subjects with preexisting cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to subitramine (4906 subjects) or a placebo (4898 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 561 subjects in the subitramine group and 490 subjects in the placebo group.16
(a) Find the proportion of subjects experiencing the primary outcome for both the subitramine and placebo groups.
(b) Can we safely use the large-sample confidence interval for comparing the proportions of subitramine and placebo subjects who experienced the primary outcome? Explain.
(c) Give a 95% confidence interval for the difference between the proportions of subitramine and placebo subjects who experienced the primary outcome.
-----------